Novel, potent, non-competitive AMPA receptor antagonist (IC50 = 2.8 μM ). Acts allosterically at the same regulatory site as GYKI 52466 and 53655 and other benzodiazepines but does not bind to the central diazepine binding site. Selective for AMPA relative to kainate receptor sub-types. Similar potency to GYKI 53655. Anticonvulsant in vivo.
Sold with the permission of Annovis Inc.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 366.42. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.73 mL||13.65 mL||27.29 mL|
|5 mM||0.55 mL||2.73 mL||5.46 mL|
|10 mM||0.27 mL||1.36 mL||2.73 mL|
|50 mM||0.05 mL||0.27 mL||0.55 mL|
References are publications that support the products' biological activity.
Bleakman et al (2002) Kainate receptor agonists, antagonists and allosteric modulators. Curr.Pharm.Des. 8 873 PMID: 11945137
Pelletier et al (1996) Substituted 1,2-dihydrophthalazines: potent, selective and non-competitive inhibitors of the AMPA receptor. J.Med.Chem. 39 343 PMID: 8558499
Li et al (1999) Kainate-receptor-mediated sensory synaptic transmission in mammalian spinal cord. Nature 397 161 PMID: 9923678
If you know of a relevant reference for SYM 2206, please let us know.
View Related Products by Product Action
Keywords: SYM 2206, supplier, Non-competitive, AMPA, antagonist, Glutamate, Receptors, iGlur, Ionotropic, SYM2206, AMPA, Receptors, AMPA, Receptors, Tocris Bioscience
7 Citations for SYM 2206
Citations are publications that use Tocris products. Selected citations for SYM 2206 include:
Nygaard et al (2015) Melanoma brain colonization involves the emergence of a brain-adaptive phenotype. J Neurophysiol 1 82 PMID: 25593989
Steullet et al (2014) Fast oscillatory activity in the anterior cingulate cortex: dopaminergic modulation and effect of perineuronal net loss. Front Cell Neurosci 8 244 PMID: 25191228
Randall et al (2011) Fast oscillatory activity induced by kainate receptor activation in the rat basolateral amygdala in vitro. Eur J Neurosci 33 914 PMID: 21255131
Kopach et al (2011) Inflammation alters trafficking of extrasynaptic AMPA receptors in tonically firing lamina II neurons of the rat spinal dorsal horn. Pain 152 912 PMID: 21282008
Liu et al (2004) Astrocyte-mediated activation of neuronal kainate receptors. Oncoscience 101 3172 PMID: 14766987
Roopun et al (2010) Cholinergic neuromodulation controls directed temporal communication in neocortex in vitro. Front Neural Circuits 4 8 PMID: 20407636
Satake et al (2006) Characterization of AMPA receptors targeted by the climbing fiber transmitter mediating presynaptic inhibition of GABAergic transmission at cerebellar interneuron-Purkinje cell synapses. J Neurosci 26 2278 PMID: 16495455
Do you know of a great paper that uses SYM 2206 from Tocris? If so please let us know.
Reviews for SYM 2206
There are currently no reviews for this product. Be the first to review SYM 2206 and earn rewards!
Have you used SYM 2206?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.